Florida Sues Prime Therapeutics and Express Scripts for Alleged Drug Price Fixing
核心洞察
Florida Attorney General James Uthmeier filed a lawsuit against Prime Therapeutics (搜索) and Express Scripts (搜索) for allegedly entering into an illegal agreement to fix drug prices.
The lawsuit cites a December 2019 collaboration in which Prime adopted Express Scripts (搜索)' lower reimbursement rates, an adjustment that remains in effect today.
Uthmeier framed the action as a matter of public safety, stating the state is "siding with our consumers over big corporations."
Florida has filed a lawsuit against two major pharmaceutical companies, Prime Therapeutics (搜索) and Express Scripts (搜索), alleging the firms entered into an illegal agreement to fix prices on otherwise affordable drugs. Attorney General James Uthmeier announced the action, describing it as a consumer-protection measure rather than a political maneuver.
"Not politics, it's public safety. It's siding with our consumers over big corporations, and ensuring that we're making sure Florida is the safest state to live, work and raise a family," Uthmeier said.
Alleged Price-Fixing Agreement
The lawsuit centers on a collaboration that took place in December 2019, when Prime Therapeutics (搜索) adopted Express Scripts (搜索)' lower reimbursement rates. According to the filing, this adjustment remains in effect today, indicating the alleged arrangement has persisted for several years.
The complaint contends that the two companies coordinated to fix prices on drugs that would otherwise be affordable, potentially raising costs for consumers and undermining competitive pricing in the pharmaceutical market.
Legal and Regulatory Significance
The case highlights ongoing scrutiny of pharmacy benefit managers and pharmaceutical pricing practices. By targeting reimbursement-rate coordination between Prime Therapeutics (搜索) and Express Scripts (搜索), the lawsuit raises questions about the boundaries between legitimate business collaboration and anticompetitive conduct in drug pricing.
The action underscores Florida's stated commitment to consumer protection in the pharmaceutical sector, with the Attorney General emphasizing public safety as the driving rationale behind the litigation.